Back to News
Nov 12, 2025 12:00 PM

Eli Lilly Drops CVS Health's Drug Benefit Plan For Employees Ahead Of 2026 Switch

Eli Lilly & Co. (NYSE:LLY) is reportedly dropping CVS Health Inc.'s (NYSE:CVS) drug benefit plan for its employees.

CVS is trading near recent highs. Review the technical setup here.

What Went Down

Earlier in May this year, Novo Nordisk A/S (NYSE:NVO) announced that CVS Health's CVS Caremark, a Pharmacy Benefit Manager (PBM), decided that Wegovy (semaglutide) injection 2.4 mg would be the preferred GLP-1 medicine on its largest commercial template formularies.

The change came into effect on July 1, 2025. 

Also Read: Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment

In March, Novo Nordisk launched NovoCare Pharmacy to provide direct-to-patient, convenient home shipments of all Wegovy dose strengths at a reduced cost of $499 per month for self-paying patients.

More recently, the Wegovy savings offer was updated, allowing eligible self-paying ...